Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

Recruiting

• Conditions: Carbapenem Resistant Bacterial Infection; Vancomycin-Resistant Enterococcal Infection; Cross Infection; Critical Illness

• Registration Number: NCT06392568
• Lead Sponsor: Abderrahmane Mami Hospital

Brief Summary

Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

Detailed Description

In 2022, a previous one-day point-prevalence multicenter study (NOSOREA2, NCT05547646) showed that most prevalent pathogens causing healthcare-associated infections were carbapenem resistant enterobacteriaceae. In 2017, (NOSOREA1, LA TUNISIE MEDICALE - 2018 ; Vol 96 (10/11)), most prevalent pathogens were non-fermenting pathogens.

Faced with this major epidemiological change within Tunisian ICUs, we decided to launch a 3rd survey under the aegis of the 'Association tunisienne de réanimation'. We aimed to investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus. So we conducted a multicenter prospective collection that will take place over 2 months.

Study Timeline

• Study First Submitted: 2024-03-30
• Status Verified: 2024-04
• Study Start: 2024-04-01
• Study First Submitted QC: 2024-04-27
• Last Update Submitted: 2024-04-27
• Study First Posted: 2024-04-30
• Last Update Posted: 2024-04-30
• Primary Completion: 2024-05-31
• Study Completion: 2024-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Adult ICU patients admitted during the study period

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Highly resistant bacterial healthcare associated infections	2 months	Incidence of eHRB healthcare associated infections in ICU
Epidemiological features of Highly resistant bacterial healthcare associated infections healthcare associated infections in ICU	2 months	Causative micro-organisms, sites and risk factors of eHRB healthcare associated infections in ICU

Trial Locations

Locations (1)

Abderrahmen Mami; 🇹🇳 Ariana, Tunis, Tunisia